Cayman Chemical Co Inc.

Cayman Chemical Co Inc., an Ann Arbor, Michigan-based manufacturer of biochemical products and research tools, sells specialized synthetic substances, drug reference materials, and analytical standards to federal law enforcement and health agencies as a prime contractor, competing full-and-open without set-asides across a heavily concentrated customer base. The company operates as a for-profit corporate entity without SBA certifications, competing predominantly on technical merit and established agency relationships rather than small-business designations.

The vendor's federal footprint is sharply concentrated by customer and dollar value. The top five funding agencies account for 97 percent of combined potential value across 525 total awards, with the Centers for Disease Control and Prevention Pittsburgh dominating at $35.9 million across 11 awards—primarily large delivery orders for Emergent Drug Panel kits ($996 thousand) and DLS Traceable Opioid Kits ($499 thousand). The Drug Enforcement Administration, despite placing 124 orders (the highest volume), contributes only $3 million in combined potential value, indicating a pattern of smaller tactical purchase orders for controlled-substance reference materials, pharmacological testing compounds, and forensic analysis standards. The Defense Health Agency and Department of the Army Medical Command together account for $4.6 million across 24 awards, focused on drug standards for service member screening and confirmation testing. This concentration creates customer-diversification risk: CDC Pittsburgh's $35.9 million represents 80 percent of total potential value, anchored on two large delivery orders scheduled to complete in late 2023 and early 2024—already within the source's observation window and suggesting substantial recompete exposure already passed or imminent.

Cayman Chemical holds two single-award indefinite delivery vehicles. The Defense Health Agency BPA, ceiling $1.5 million through September 2027, authorizes procurement of chemicals, synthetic cannabinoids, and novel psychoactive substances for military drug testing. The Department of the Army Medical Command BPA, ceiling $130,000 through September 2022, supplies chemical standards to the Army Forensic Toxicology Drug Testing Laboratory in San Antonio, Texas. Task order activity under the top agency-held vehicles is thin: the highest-volume BPA (W9124912A0005) carries 8 task orders valued at $31 thousand, suggesting these vehicles serve as standing purchase authorities rather than primary revenue engines. A CDC Indefinite Delivery Contract (75D30119D06777) generated 5 task orders worth $5.9 million, consistent with the large CDC delivery order portfolio.

Activity trajectory shows recent contraction. The vendor recorded 15 awards in 2022, 18 in 2023, then declined to 8 in 2024 and 7 in 2025, with only 1 award in 2026 year-to-date. This downturn mirrors the CDC's DLS Traceable Opioid Kits awards completing in 2023, suggesting that loss of major CDC task orders drove the volume decline. Recompete exposure in the next twenty-four months is minimal: only 2 awards worth $230 thousand face completion, indicating most recent awards already account for historical completions or extended periods of performance.

Cayman Chemical's capability portfolio reflects its position as a specialized biochemical supplier. On the law enforcement side, it synthesizes controlled substances, opioids, and novel psychoactive compounds (fentanyl analogs, fluetonitazene, ortho-methylfentanyl) in small quantities (500 mg to 1 gram) for DEA pharmacological testing, diversion control, and abuse potential evaluation. A January 2026 DEA purchase order for $230 thousand for drug-substance synthesis and a May 2025 DEA order for $95.7 thousand for 14 chemical substances exemplify this work. On the public-health side, the vendor manufactures analytical kits—the CDC's Emergent Drug Panel-Version 1 and DLS Traceable Opioid Kits—and supplies drug standards and screening reagents for military and civilian drug-testing laboratories. For the National Cancer Institute, Cayman performs mass-spectrometry sample analysis and peptide profiling across multiple small purchase orders (2022–2023, $22–24 thousand each), supporting immunopeptidome research. The vendor holds primary NAICS codes in All Other Basic Organic Chemical Manufacturing (209 awards) and All Other Miscellaneous Chemical Product Manufacturing (10 awards), with PSC codes concentrated in Laboratory Equipment and Supplies (207 awards) and Chemicals (142 awards).

Federal grant activity is research-focused and modest in volume. Cayman Chemical holds two active National Institute of Dental and Craniofacial Research project grants as recipient: one awarded April 2025 (ultimate completion April 2027) for epigenetic compounds stimulating dental bone repair targeting periodontitis and alveolar bone regeneration, and one awarded September 2021 (ultimate completion August 2025) for a novel small molecule (KMN-159, an EP4 receptor agonist) to improve dental implant osseointegration. Both grants reflect Cayman's medicinal-chemistry R&D capability and position the company as a drug-development partner to NIH beyond its core role as a reference-materials supplier. Subcontract activity is minimal: the vendor subcontracts to Research Triangle Institute on a medications-development contract and serves as an expert panelist on a Fredric Rieders Family Renaissance Foundation sub-grant focused on novel psychoactive substance naming and data triangulation.

Cayman Chemical's federal business is transactional and supplier-focused rather than strategic. The absence of GWACs, large multiple-award contracts, or team leadership suggests the vendor operates as a sole-source specialist: agencies value its synthetic-compound manufacturing and analytical kit capabilities and return repeatedly for tactical orders, but the company has not positioned itself to compete for large blanket requirements or integrator roles. The recent contraction in award volume and potential-value concentration on CDC opioid kits—a mission-critical but time-limited public-health initiative—present medium-term pipeline risk if the CDC reduces opioid surveillance or consolidates suppliers.